ES2570452A1 - Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas - Google Patents

Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas

Info

Publication number
ES2570452A1
ES2570452A1 ES201400810A ES201400810A ES2570452A1 ES 2570452 A1 ES2570452 A1 ES 2570452A1 ES 201400810 A ES201400810 A ES 201400810A ES 201400810 A ES201400810 A ES 201400810A ES 2570452 A1 ES2570452 A1 ES 2570452A1
Authority
ES
Spain
Prior art keywords
alkylamino
translation
treatment
machine
legally binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201400810A
Other languages
English (en)
Other versions
ES2570452B1 (es
Inventor
Martinez Rafael Leon
Abaitua Izaskun Buendia
Gonzalez De Mesa Elisa Navarro
Patrycja Michalska
Ros Isabel Gameiro
Vivo Alicia Lopez
Maiquez Javier Egea
Lopez Manuela Garcia
Garcia Antonio Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dns Neuroscience
Universidad Autonoma de Madrid
Fundacion para la Investigacion Biomedica del Hospital Universitario de la Princesa
Original Assignee
Dns Neuroscience
Universidad Autonoma de Madrid
Fundacion para la Investigacion Biomedica del Hospital Universitario de la Princesa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dns Neuroscience, Universidad Autonoma de Madrid, Fundacion para la Investigacion Biomedica del Hospital Universitario de la Princesa filed Critical Dns Neuroscience
Priority to ES201400810A priority Critical patent/ES2570452B1/es
Priority to EP15851060.2A priority patent/EP3208262A4/en
Priority to US15/518,223 priority patent/US20180105492A1/en
Priority to PCT/ES2015/000139 priority patent/WO2016059269A1/es
Priority to CA2964309A priority patent/CA2964309A1/en
Publication of ES2570452A1 publication Critical patent/ES2570452A1/es
Application granted granted Critical
Publication of ES2570452B1 publication Critical patent/ES2570452B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los métodos de obtención de derivados de acrilato de 3-alquilamino-1H-indolilo con actividad inductora del factor de transcripción Nrf2, actividad secuestradora de radicales libres y capacidad neuroprotectora. Otro aspecto de la invención se refiere al uso de los derivados objeto de esta invención para el tratamiento de enfermedades en cuya patogénesis interviene el de estrés oxidativo o enfermedades que cursen con desregulación de la actividad de genes de fase dos activados por el factor Nrf2, como la enfermedad de Alzheimer, la enfermedad de Parkinson, la enfermedad de Huntington, la esclerosis múltiple, el ictus o la esclerosis lateral amiotrófica.
ES201400810A 2014-10-15 2014-10-15 Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas Withdrawn - After Issue ES2570452B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201400810A ES2570452B1 (es) 2014-10-15 2014-10-15 Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
EP15851060.2A EP3208262A4 (en) 2014-10-15 2015-10-15 Compounds derived from 3-alkylamino-1h-indole acrylate, and the use thereof in the treatment of neurodegenerative diseases
US15/518,223 US20180105492A1 (en) 2014-10-15 2015-10-15 Compounds derived from 3-alkylamine-1h-indolyl acrylate and their use in the treatment of neurodegenerative diseases
PCT/ES2015/000139 WO2016059269A1 (es) 2014-10-15 2015-10-15 Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
CA2964309A CA2964309A1 (en) 2014-10-15 2015-10-15 Compounds derived from 3-alkylamine-1h-indolyl acrylate and their use in the treatment of neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201400810A ES2570452B1 (es) 2014-10-15 2014-10-15 Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas

Publications (2)

Publication Number Publication Date
ES2570452A1 true ES2570452A1 (es) 2016-05-18
ES2570452B1 ES2570452B1 (es) 2017-04-19

Family

ID=55746171

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201400810A Withdrawn - After Issue ES2570452B1 (es) 2014-10-15 2014-10-15 Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas

Country Status (5)

Country Link
US (1) US20180105492A1 (es)
EP (1) EP3208262A4 (es)
CA (1) CA2964309A1 (es)
ES (1) ES2570452B1 (es)
WO (1) WO2016059269A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126950C2 (uk) 2018-08-20 2023-02-22 Янссен Фармацевтика Нв Інгібітори міжбілкової взаємодії keap1-nrf2
ES2946307A1 (es) * 2022-01-14 2023-07-14 Consejo Superior Investigacion Compuestos inductores de nrf2 e inhibidores de mao-b para el tratamiento de la enfermedad de parkinson
ES2957638A1 (es) * 2022-06-15 2024-01-23 Univ Rey Juan Carlos (e)-3-(4-hidroxi-3-metoxifenil)-acrilato de 3-(2-acetamidoetil)-1h-indol-5-ilo para uso en la prevencion y/o tratamiento de la hipertension arterial y las alteraciones cardiovasculares asociadas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
CA2234166A1 (en) * 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
AU2002303094B2 (en) * 2001-03-29 2006-11-23 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
AU2012222074A1 (en) * 2011-02-25 2013-09-12 National Institutes Of Health Chalcone derivatives as Nrf2 activators
US8916604B2 (en) * 2011-05-31 2014-12-23 Rutgers, The State University Of New Jersey Compositions and methods for epigenetic modification of nucleic acid sequences

Also Published As

Publication number Publication date
US20180105492A1 (en) 2018-04-19
WO2016059269A1 (es) 2016-04-21
EP3208262A1 (en) 2017-08-23
EP3208262A4 (en) 2018-05-02
CA2964309A1 (en) 2016-04-21
WO2016059269A8 (es) 2017-05-26
ES2570452B1 (es) 2017-04-19

Similar Documents

Publication Publication Date Title
AU2019268063A1 (en) Compositions for modulating sod-1 expression
TW201613901A (en) New compounds
EA201691514A1 (ru) Соединения
PH12016501702B1 (en) Pyrazole amide derivative
ZA201605341B (en) Methods of treating alzheimer's disease
IL247085B (en) Methods for treating Alzheimer's disease
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
ECSP16070327A (es) Heteroaril amidas como inhibidores de agregación de proteína
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
NZ709399A (en) Method of treatment of hypoxia inducible factor (hif)-related conditions
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
ES2570452A1 (es) Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2016000724A (es) Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
MX2017006692A (es) Trastornos neurodegenerativos.
BR112016016098A2 (pt) Compostos orgânicos
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
EP3244897A4 (en) Methods for treating alzheimer's disease
BR112016021408A2 (pt) métodos para o tratamento da doença de alzheimer utilizando compostos derivados de 6-estradiol substituído
BR112016016138A2 (pt) Novos 1,3-benzenodióis funcionalizados e método de uso dos mesmos para o tratamento da encefalopatia hepática
BR112017000127A2 (pt) Nova forma polimórfica de cloridrato de n-[2-(6- fluoro-1h-indol-3-il)etil]-3-(2,2,3,3- tetrafluoropropoxi)benzilamina para o tratamento da doença de alzheimer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2570452

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20170419

FA2A Application withdrawn

Effective date: 20171020